NCT02099708

Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs

Takepron Capsules 15/ Orally Dispersing（OD） Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,502 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the safety and efficacy of long-term administration of lansoprazole (Takepron) therapy for up to 12 months in the routine clinical setting in patients receiving oral non-steroidal anti-inflammatory drugs (NSAIDs)

Detailed description

This is a special survey on long-term use (for up to 12 months) of lansoprazole (Takepron) to determine the incidence of adverse drug reactions in the routine clinical setting in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs). The usual adult dosage is 15 mg of lansoprazole administered orally once daily.

Conditions

• Gastric or Duodenal Ulcers

Interventions

Type	Name	Description
DRUG	Lansoprazole	Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg

Timeline

• Start date: 2010-10-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2014-03-31
• Last updated: 2016-10-27
• Results posted: 2015-10-09